In 2020, Lars Fruergaard Jørgensen was the highest-paid top executive among Denmark's elite companies. It's hard to strike the right balance, says the Novo Nordisk Chair.
Suspicions of patent maneuvers and smear campaigns against competitors lead the EU Commission to scrutinize pharmaceutical company Teva.
Chair of the Novo Nordisk Board Helge Lund thinks tax payers will be paying a large bill for the Covid-19 crisis. He also expects an additional pressure to fall on the pharmaceutical industry in future years.
Denmark wishes to establish a Covid-19 research fund with Israel and Austria and explore the possibility of a joint vaccine production with the two countries, according to the parties at a press conference.
Miss anything?
US pharmaceutical firm Eli Lilly has presented its long-awaited data for drug candidate tirzepatide in a direct comparison study with Novo Nordisk's semaglutide. The US candidate takes top prize.
Fujifilm Diosynth Biotechnologies has started expanding its production facility in Denmark. The firm bought the factory from Biogen last year.
Even though Eli Lilly presented strong data in a comparison study between this company's drug tirzepatide and Novo Nordisk's rival semaglutide, it'll take more to eliminate the Danish competition, according to an analyst.
Denmark, Israel and some other countries have had meetings on a regular basis, according to an ambassador.
The EMA has started reviewing the Russian Covid-19 vaccine Sputnik V. This will ensure faster approval, if the Russians file for EU approval for the vaccine.
Orphazyme's CFO and and interim CEO Anders Vadsholt is vocal that 2021 can be an important year for the biotech company.
According to database Clinical Trials, Novo Nordisk will launch clinical trials for the company's diabetes drug semaglutide in tablet form as a possible treatment for Alzheimer's in end-May.
Danish PM Mette Frederiksen declares interest in the idea of Denmark establishing vaccine factories in collaboration with Israel just before traveling to this country, where she will discuss vaccine infrastructure with Israeli PM Benjamin Netanyahu.
Denmark, Austria and Israel have contacted several companies in connection with a potential collaboration on vaccine production, states Israeli Ambassador to Denmark Benny Dagan, according to Børsen.
Nordic Bioscience's owner group has sold a minority stake in the company to global investment company KKR for USD 100m.
Genmab and Lundbeck currently belong in the exclusive club of C25 companies that are integrating ESG indicators into their management incentive compensation plans.
Orphazyme's newly appointed CEO is of a different build than his predecessor, Kim Stratton, as his management style is more transparent and inclusive, according to Vice Chairman Bo Jesper Hansen, who is excited that the new top exec is moving to Denmark and already learning the language.
Lundbeck shares may gain added value, if the firm successfully expands the number of diseases that can be treated with its Rexulti treatment, according to financial services group.
Orphazyme predicts lower operating result in transformational 2021.
The black market for vaccine doses in the EU is rapidly growing with both fraudsters and companies claiming to sell vaccines.
In 2021, Novo Nordisk Pharmatech will open up a US sales office. With this, the firm will have representation in Denmark, Singapore and the US.
Just over two months after Orphazyme bid former CEO Kim Stratton farewell, the firm has found her replacement at US biotech firm Amgen.
Another deal has fallen into place between Boehringer Ingelheim and the Danish biotech and contract research firm Gubra. The parties have entered into lucrative deals in the past, but will not disclose the financial terms underlying the new agreement.
Novo Nordisk may see accelerated sales of obesity drugs sooner than expected, thinks Danish bank analyst, who sees great potential in upcoming new data for semaglutide as an obesity treatment.
The EMA has accepted Pfizer's and Opko's application to get a new growth hormone approved, which may compete with Novo Nordisk's and Ascendis' growth hormons.
Pharmacovigilance Manager - Vaccibody 
Merck – Director Market Access 
Associate Director, Global Drug Safety and Pharmacovigilance Scientist - Genmab 
Regulatory Affairs Life Cycle Associate 
Director CMC, Drug Product - Galecto 
Chemist for pilot facility and process development - ALK 
Sales and Business Development Manager @Bioneer 
Principal Scientist - Y-mAbs Therapeutics A/S 
Director of Product Technology, Aligned Bio Head of Clinical Operations - Vaccibody Alliance Manager, Business Development Department - Y-mAbs Therapeutics Associate Director, Clinical Systems, Gensense Analytics & Visualizations - Genmab Senior Immunoassay Scientist, Aligned Bio Director, Team Lead, GCP/PV QA - Genmab 
Senior Regulatory Affairs consultant in medical equipment Medical Writer - Genmab 
Medical Affairs Director – Ascelia Pharma 
Associate Director Medical Science – Orphazyme 
CMC Project Manager – MC2 Therapeutics 
Devote Consulting is looking for a new Senior Consultant Manager/Senior Manager, IT QA - Genmab Regulatory Affairs Manager – MC2 Therapeutics Associate Director, GMP QA, Commercial Operations – Y-mAbs Therapeutics 
Business development manager – IWA consulting Regulatory Affairs Professional - ALK 
